Palatin Technologies Q4 2026 Earnings Report

Palatin Technologies EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.20
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Palatin Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Palatin Technologies Announcement Details

• Quarter: Q4 2026
• Date: 9/2/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Palatin Technologies (NYSEAMERICAN:PTN), Inc. (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization. Its pipeline has historically included multiple candidate programs at various stages of development, and the company has sought to progress those programs through clinical trials while evaluating potential collaborations to broaden development resources and market access.

Palatin operates in the United States and engages with the broader biopharma ecosystem to advance its products. Publicly traded on the NYSE American exchange, the company has worked to leverage scientific expertise and external partnerships to move assets forward. I do not have fully verifiable, up-to-date details on current executive leadership or recent corporate milestones; readers should consult the company’s filings and official releases for the latest leadership, pipeline and strategic information.